MedTrace Logo

The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty

NCT00909064 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2017-05-15

Study results available
· View outcomes & findings →

Summary

The investigators hypothesize that Arixtra patients will be less likely to experience wound infection than patients who have received low-molecular weight heparin, coumadin or aspirin with mechanical compression.

Conditions

  • Total Knee Replacement

Interventions

DRUG

Fondaparinux Sodium (Arixtra)

2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.

Sponsors & Collaborators

  • Paul Di Cesare,MD

    lead OTHER

Principal Investigators

  • Paul E. DiCesare, MD · University of California, Davis Health System

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00909064 on ClinicalTrials.gov